Milsaperidone

Milsaperidone is an atypical antipsychotic with two FDA-approved uses, both specific to the Bysanti brand oral tablet in adults:

• Schizophrenia: Bysanti is approved for the ongoing treatment of schizophrenia in adults.
• Bipolar I disorder (acute mania): Bysanti is approved for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
• Bysanti is not approved for dementia-related psychosis or for use in children and adolescents.

Milsaperidone is thought to work by blocking two key types of receptors in the brain: dopamine D2 receptors and serotonin 5-HT2 receptors. Dopamine and serotonin are chemical messengers that, when out of balance, are linked to symptoms of schizophrenia and mania. By blocking these receptors, milsaperidone helps rebalance these signals. The drug also blocks several other receptor types — including norepinephrine and histamine receptors — which may contribute to some of its side effects such as dizziness and sedation.

Milsaperidone and a related compound called iloperidone rapidly convert back and forth into each other inside the body, meaning both compounds are active at the same time and both contribute to how the medication works.

Bysanti tablets are taken by mouth twice daily and can be taken with or without food. Treatment must begin with a low dose that is gradually increased over several days — this step-up approach is essential to reduce the risk of dizziness and a blood pressure drop when standing. Steady, stable drug levels in the blood are typically reached within 3 to 4 days of consistent dosing.

• If you miss more than three consecutive days of Bysanti, do not simply resume where you left off — contact your prescriber, as you may need to restart the gradual dose-increase schedule.
• People who metabolize the drug more slowly (CYP2D6 poor metabolizers) follow a different, lower-dose titration schedule — your prescriber may order a genetic test to determine which schedule applies to you.

The most commonly reported side effects of Bysanti (occurring in at least 5% of patients and at least twice as often as with placebo) include:

• Dizziness
• Drowsiness or sedation
• Dry mouth
• Fast heart rate (tachycardia)
• Nasal congestion
• Low blood pressure when standing (orthostatic hypotension)
• Fatigue
• Weight gain

More serious reactions — including dangerous heart rhythm changes, neuroleptic malignant syndrome (a rare but potentially fatal condition involving fever, muscle rigidity, and confusion), tardive dyskinesia (uncontrolled muscle movements), and significant changes in blood sugar or cholesterol — require prompt medical attention. Contact your doctor or seek emergency care if you experience any of these.

• QTc prolongation (heart rhythm effect): Bysanti can lengthen the QTc interval — an electrical measurement of the heart's rhythm — which can lead to a dangerous arrhythmia. Avoid other drugs that affect heart rhythm, and have your potassium and magnesium levels checked, especially if you are at risk.
• Neuroleptic malignant syndrome (NMS): A rare but life-threatening reaction that can include very high fever, severe muscle rigidity, altered thinking, and unstable heart rate or blood pressure. Stop Bysanti and get emergency care immediately if this is suspected.
• Tardive dyskinesia: Long-term use of antipsychotics, including Bysanti, can cause uncontrolled, repetitive muscle movements that may persist or become permanent. Elderly women appear to be at highest risk. Tell your doctor right away if you notice unusual movements.
• Metabolic changes: Bysanti can raise blood sugar, worsen cholesterol, and cause weight gain — all factors that increase cardiovascular risk. Blood sugar should be monitored, especially with long-term use.
• Orthostatic hypotension and falls: Blood pressure can drop sharply when you stand up, especially early in treatment. Rise slowly and use caution with activities requiring balance.
• Low white blood cell count: In patients with a history of low white blood cell counts or previous drug-related blood count problems, close monitoring is needed and Bysanti should be stopped if counts fall dangerously low.
• Dementia-related psychosis: Bysanti must NOT be used in elderly patients with dementia-related psychosis — this population faces a significantly increased risk of death with antipsychotic drugs.

Several types of medications can significantly affect how Bysanti works or increase the risk of side effects:

• Strong CYP2D6 inhibitors (e.g., paroxetine and similar drugs): Slow the breakdown of Bysanti, raising drug levels in the blood and increasing side-effect risk — a dose reduction is required.
• Strong CYP3A4 inhibitors (e.g., ketoconazole and similar drugs): Also slow Bysanti's metabolism, raising blood levels — a dose reduction is required.
• Combined CYP2D6 + CYP3A4 inhibitors: Taking both types at the same time raises Bysanti levels even more — dose must be reduced and carefully managed.
• QTc-prolonging medications: Other drugs that affect the heart's electrical rhythm should be avoided alongside Bysanti, as the combined effect can significantly increase the risk of a dangerous arrhythmia.
• Alpha-adrenergic blockers (certain blood pressure medications): Should be avoided with Bysanti due to the added risk of severe low blood pressure.
• Other blood pressure-lowering drugs: May need dose adjustments when used with Bysanti, as the combination can cause blood pressure to drop too much.

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

• Do not take Bysanti if you have ever had a serious allergic reaction (anaphylaxis, severe swelling) to milsaperidone or any ingredient in Bysanti.
• Tell your prescriber if you are pregnant — babies exposed to antipsychotics in the third trimester can experience temporary muscle problems or withdrawal symptoms after birth. A pregnancy registry is available at 1-866-961-2388 for those exposed during pregnancy.
• Do not breastfeed while on Bysanti. Wait at least 6 days after your last dose (or 8 days if you are a CYP2D6 poor metabolizer) before breastfeeding.
• Tell your prescriber about any liver problems — Bysanti is not recommended for severe liver impairment; moderate liver impairment may require a lower dose.
• Inform your prescriber of any history of heart rhythm problems, low potassium or magnesium, seizures, diabetes, or low white blood cell counts.
• Bysanti is not approved for children or adolescents; safety and effectiveness have not been established in this age group.
• Elderly patients with dementia-related psychosis must not use Bysanti — the risk of death is significantly increased in this group.
• Let your prescriber know about all medications you currently take, as several common drugs can interact with Bysanti and require dose adjustments.
• If you are planning surgery, tell your surgical team you take Bysanti — an eye-related condition called intraoperative floppy iris syndrome has been associated with antipsychotic use.

Taking too much Bysanti may cause excessive drowsiness, sedation, fast heart rate, low blood pressure, and in serious cases, heart rhythm changes or seizures. If an overdose is suspected, call the Poison Help Line at 1-800-222-1222 or seek emergency care immediately. There is no specific antidote — treatment focuses on supportive care including airway management and continuous heart monitoring.

Milsaperidone blocks multiple receptor types in the brain and nervous system, including dopamine, serotonin, norepinephrine, and histamine receptors. Its strongest blocking action is at serotonin 5-HT2A receptors, which is thought to be especially important for its antipsychotic effects. It can also affect the heart's electrical activity: studies with the closely related compound iloperidone showed QTc interval prolongation (a measurable change in the heart's rhythm on an ECG), and this effect is greater when certain enzyme-blocking medications are taken at the same time or in people who metabolize the drug slowly.

After taking Bysanti by mouth, milsaperidone reaches its peak concentration in the blood within about 4 hours, and stable steady-state levels are typically reached within 3 to 4 days of twice-daily dosing. The drug is broken down mainly in the liver, with milsaperidone and iloperidone continuously interconverting; people who are slow metabolizers (CYP2D6 poor metabolizers) clear the drug more slowly, resulting in longer half-lives (about 37 hours for milsaperidone, versus 26 hours in normal metabolizers). The drug and its byproducts are eliminated primarily through the urine. Food does not significantly affect how the body absorbs Bysanti.

Store the tablets at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15° to 30 °C (59°F to 86°F) .